N/A N=130 Diagnostic

Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects

Cystic Fibrosis · Liver Fibrosis

Bottom Line

View on ClinicalTrials.gov: NCT02603666 ↗

Enrolled (actual)

130

Serious AEs

0.0%

Results posted

Dec 2016

Primary outcome: Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Fibroscan (Device)
Age: Pediatric, Adult, Older Adult · 1+ yrs
Sex: All
Sponsor: Karolinska University Hospital
Primary completion: Jun 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Elastographic Value in kPa Measured by Fibroscan	4.7	—

Summary

The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological evaluation of liver biopsy if present.

Eligibility Criteria

Inclusion Criteria

Verified cystic fibrosis

Exclusion Criteria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02603666). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.